| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.29 | 1e-17 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.23 | 6e-11 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-09 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-08 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.25 | 2e-06 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.24 | 8e-06 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |